Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509782 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of ZIO-101 in Patients With Solid Tumors
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00509782: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00509782 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00509782, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
Primary Objectives: 1. To determine the toxicities and maximum tolerated dose (MTD) of ZIO-101 when administered intravenously once a day for 5 consecutive days every 4 weeks in subjects with advanced solid tumors. 2. To determine the pharmacokinetic profile of ZIO-101 when administered intravenously once a day for 5 consecutive days every 4 weeks. Secondary Objective: 1\. To determine the anti-tumor effects of ZIO-101.
Interventions
- DRUG ZIO-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00509782
The ClinicalTrials.gov registry entry for NCT00509782 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZIO-101 is the first listed.
NCT00509782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00509782 about?
NCT00509782 is a clinical study titled "Phase I Trial of ZIO-101 in Patients With Solid Tumors". Primary Objectives: 1. To determine the toxicities and maximum tolerated dose (MTD) of ZIO-101 when administered intravenously once a day for 5 consecutive days every 4 weeks in subjects with advanced solid tumors. 2. To determine the pharmacokinetic profile of ZIO-101 when administered intravenous...
What is the current status of trial NCT00509782?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2005-05. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00509782?
The interventions under investigation include: ZIO-101 (DRUG).
Who is sponsoring clinical trial NCT00509782?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.